Palisade Bio Secures Japanese Patent for PALI-2108, Phase 2 Trials Planned for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Should l Buy PALI?
Source: Globenewswire
- Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, which extends until 2041, ensuring a unique competitive advantage in the Japanese market to meet the urgent needs of ulcerative colitis and Crohn's disease patients.
- Clinical Progress: PALI-2108 demonstrated a 100% clinical response rate in Phase 1 trials with no serious adverse events, laying a solid foundation for the upcoming Phase 2 IND submission planned for the first half of 2026.
- Market Potential: Japan represents one of the largest markets for inflammatory bowel disease globally, and the patent acquisition will enhance Palisade Bio's strategic position in this market, expected to significantly boost product acceptance and sales potential.
- Innovative Drug Development: PALI-2108 is designed for local delivery to minimize systemic side effects, which is anticipated to provide safer treatment options for patients, thereby driving the company's long-term growth in chronic inflammatory and fibrotic diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PALI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PALI
Wall Street analysts forecast PALI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PALI is 13.00 USD with a low forecast of 7.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.500
Low
7.00
Averages
13.00
High
25.00
Current: 1.500
Low
7.00
Averages
13.00
High
25.00
About PALI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palisade Bio's PALI-2108 Clinical Data Selected for Two International IBD Meetings
- Clinical Data Presentation: Palisade Bio's PALI-2108 has been selected for poster presentations at two international inflammatory bowel disease meetings in January and February 2026, showcasing the drug's potential in ulcerative colitis treatment and enhancing the company's reputation in the biopharmaceutical sector.
- Immune Balance Restoration: PALI-2108 rapidly restores immune-epithelial balance in ulcerative colitis patients through gut-targeted PDE4B inhibition, indicating its clinical efficacy and potentially providing new treatment options for patients.
- Successful Clinical Trials: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which strengthens its market competitiveness.
- Future Research Plans: Palisade Bio plans to initiate a Phase 2 clinical study for PALI-2108 in 2026 to evaluate clinical remission and pharmacodynamic biomarkers in ulcerative colitis, further validating its therapeutic effects and expanding its indications.
See More
Palisade Bio Secures $500K Investment to Advance PALI-2108
- Strategic Investment: The Crohn’s & Colitis Foundation has approved a strategic equity investment of up to $500,000 in Palisade Bio through its IBD Ventures program, aimed at supporting the clinical and mechanistic development of PALI-2108, reflecting strong endorsement of the drug's potential.
- Clinical Progress: PALI-2108 achieved a 100% clinical response in the UC cohort with no serious adverse events, indicating favorable tolerability and pharmacokinetics in treating moderate to severe ulcerative colitis and fibrostenotic Crohn’s disease.
- R&D Plans: Palisade Bio is preparing to submit a Phase 2 Investigational New Drug application to the FDA in 2026 for PALI-2108, further advancing its clinical development to meet the urgent need for non-immunosuppressive therapies for patients.
- Market Potential: The targeted delivery design of PALI-2108 aims to minimize systemic side effects while maximizing anti-inflammatory and anti-fibrotic effects, which is expected to significantly enhance treatment options for IBD patients and strengthen the company's competitive position in the biopharmaceutical sector.
See More
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
- Stock Surge: Momentus Inc. shares soared 57% to $8.98 following the announcement of an additive-manufactured fuel tank, indicating strong market confidence in its aerospace service potential.
- Flight Testing Plans: The fuel tank is scheduled for flight testing aboard the Vigoride-7 orbital service vehicle, which not only enhances the company's technological capabilities but also opens new revenue streams for future commercial launches.
- FDA Clearance: GH Research PLC shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application, marking a significant breakthrough in the company's development process that could accelerate product commercialization.
- Market Volatility: Despite a generally positive market, Zenas Biopharma Inc. shares plummeted 57% due to results from the INDIGO trial, reflecting the high-risk nature of the biopharmaceutical sector, necessitating cautious investment evaluations.
See More
Palisade Bio Secures Japanese Patent for PALI-2108, Phase 2 Trials Planned for 2026
- Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, which extends until 2041, ensuring a unique competitive advantage in the Japanese market to meet the urgent needs of ulcerative colitis and Crohn's disease patients.
- Clinical Progress: PALI-2108 demonstrated a 100% clinical response rate in Phase 1 trials with no serious adverse events, laying a solid foundation for the upcoming Phase 2 IND submission planned for the first half of 2026.
- Market Potential: Japan represents one of the largest markets for inflammatory bowel disease globally, and the patent acquisition will enhance Palisade Bio's strategic position in this market, expected to significantly boost product acceptance and sales potential.
- Innovative Drug Development: PALI-2108 is designed for local delivery to minimize systemic side effects, which is anticipated to provide safer treatment options for patients, thereby driving the company's long-term growth in chronic inflammatory and fibrotic diseases.
See More
Palisade Bio Secures Japanese Patent for PALI-2108, IND Submission Planned for 2026
- Strengthened Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, effective until 2041, which enhances the company's intellectual property foundation in the inflammatory bowel disease (IBD) sector, potentially boosting market competitiveness.
- Accelerated Clinical Progress: The ongoing development of PALI-2108 for UC and FSCD is on track, with an IND submission to the FDA planned for the first half of 2026, which, if successful, will provide more effective treatment options for patients and meet market demand.
- Significant Clinical Trial Results: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in UC patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which may enhance market acceptance.
- Substantial Market Potential: Japan represents one of the largest markets for IBD globally, and the patent protection along with clinical advancements for PALI-2108 will help the company capture long-term growth opportunities in the region while improving patient outcomes.
See More
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
See More
Palisade Bio's PALI-2108 Clinical Data Selected for Two International IBD Meetings
- Clinical Data Presentation: Palisade Bio's PALI-2108 has been selected for poster presentations at two international inflammatory bowel disease meetings in January and February 2026, showcasing the drug's potential in ulcerative colitis treatment and enhancing the company's reputation in the biopharmaceutical sector.
- Immune Balance Restoration: PALI-2108 rapidly restores immune-epithelial balance in ulcerative colitis patients through gut-targeted PDE4B inhibition, indicating its clinical efficacy and potentially providing new treatment options for patients.
- Successful Clinical Trials: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which strengthens its market competitiveness.
- Future Research Plans: Palisade Bio plans to initiate a Phase 2 clinical study for PALI-2108 in 2026 to evaluate clinical remission and pharmacodynamic biomarkers in ulcerative colitis, further validating its therapeutic effects and expanding its indications.
See More
Palisade Bio Secures $500K Investment to Advance PALI-2108
- Strategic Investment: The Crohn’s & Colitis Foundation has approved a strategic equity investment of up to $500,000 in Palisade Bio through its IBD Ventures program, aimed at supporting the clinical and mechanistic development of PALI-2108, reflecting strong endorsement of the drug's potential.
- Clinical Progress: PALI-2108 achieved a 100% clinical response in the UC cohort with no serious adverse events, indicating favorable tolerability and pharmacokinetics in treating moderate to severe ulcerative colitis and fibrostenotic Crohn’s disease.
- R&D Plans: Palisade Bio is preparing to submit a Phase 2 Investigational New Drug application to the FDA in 2026 for PALI-2108, further advancing its clinical development to meet the urgent need for non-immunosuppressive therapies for patients.
- Market Potential: The targeted delivery design of PALI-2108 aims to minimize systemic side effects while maximizing anti-inflammatory and anti-fibrotic effects, which is expected to significantly enhance treatment options for IBD patients and strengthen the company's competitive position in the biopharmaceutical sector.
See More
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
- Stock Surge: Momentus Inc. shares soared 57% to $8.98 following the announcement of an additive-manufactured fuel tank, indicating strong market confidence in its aerospace service potential.
- Flight Testing Plans: The fuel tank is scheduled for flight testing aboard the Vigoride-7 orbital service vehicle, which not only enhances the company's technological capabilities but also opens new revenue streams for future commercial launches.
- FDA Clearance: GH Research PLC shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application, marking a significant breakthrough in the company's development process that could accelerate product commercialization.
- Market Volatility: Despite a generally positive market, Zenas Biopharma Inc. shares plummeted 57% due to results from the INDIGO trial, reflecting the high-risk nature of the biopharmaceutical sector, necessitating cautious investment evaluations.
See More
Palisade Bio Secures Japanese Patent for PALI-2108, Phase 2 Trials Planned for 2026
- Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, which extends until 2041, ensuring a unique competitive advantage in the Japanese market to meet the urgent needs of ulcerative colitis and Crohn's disease patients.
- Clinical Progress: PALI-2108 demonstrated a 100% clinical response rate in Phase 1 trials with no serious adverse events, laying a solid foundation for the upcoming Phase 2 IND submission planned for the first half of 2026.
- Market Potential: Japan represents one of the largest markets for inflammatory bowel disease globally, and the patent acquisition will enhance Palisade Bio's strategic position in this market, expected to significantly boost product acceptance and sales potential.
- Innovative Drug Development: PALI-2108 is designed for local delivery to minimize systemic side effects, which is anticipated to provide safer treatment options for patients, thereby driving the company's long-term growth in chronic inflammatory and fibrotic diseases.
See More
Palisade Bio Secures Japanese Patent for PALI-2108, IND Submission Planned for 2026
- Strengthened Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, effective until 2041, which enhances the company's intellectual property foundation in the inflammatory bowel disease (IBD) sector, potentially boosting market competitiveness.
- Accelerated Clinical Progress: The ongoing development of PALI-2108 for UC and FSCD is on track, with an IND submission to the FDA planned for the first half of 2026, which, if successful, will provide more effective treatment options for patients and meet market demand.
- Significant Clinical Trial Results: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in UC patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which may enhance market acceptance.
- Substantial Market Potential: Japan represents one of the largest markets for IBD globally, and the patent protection along with clinical advancements for PALI-2108 will help the company capture long-term growth opportunities in the region while improving patient outcomes.
See More
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
See More
